<DOC>
	<DOCNO>NCT03075579</DOCNO>
	<brief_summary>Diurnal profile marker stress system increasingly recognize biomarkers different kind depression relate state . They may also serve marker treatment success . However , yet study attention deficit disorder ( ADHD ) . Especially , paucity research effect ADHD medication diurnal profile cortisol marker hypothalamic pituitary adrenal ( HPA ) system amylase marker sympathetic adrenomedullar ( SAM ) system . The investigator propose within subject design probands narrow age range ( seven ten year age , sex : boy ) order get first information whether effect atomoxetine diurnal profile cortisol amylase , kind effect whether effect relate treatment success . The investigator control motor activity use actometer measurement .</brief_summary>
	<brief_title>Atomoxetine , Diurnal Profiles Cortisol α-amylase</brief_title>
	<detailed_description>Scientific clinical Background There good evidence hypothalamic-pituitary- adrenal ( HPA ) axis disturb depression . There evidence stress system also play role attention deficit disorder ( ADHD ) ( O'Connor , Heron et al . 2002 ) . The investigator show motor activity attention deficit/concentration core symptom depression ( Kammerer , Marks et al . 2009 ; Kammerer 2010 ) . These symptom also core symptom attention deficit hyperkinetic disorder ( ADHD ) . There increase evidence diurnal variation marker stress system ( e.g . salivary cortisol hypothalamic pituitary adrenal ( HPA ) axis , salivary amylase sympathetic adrenomedullar ( SAM ) axis ) reveal characteristic different type depression , e.g . atypical depression ( Tops , Riese et al . 2008 ) , post partum depression ( Tops , Riese et al . 2008 ; Taylor , Glover et al . 2009 ) relate state , e.g . posttraumatic stress disorder ( PTSD ) ( Wessa , Rohleder et al . 2006 ) chronic fatigue syndrome ( Roberts , Wessely et al . 2004 ) . There evidence saliva cortisol level cortisol awaken rise may markers treatment success ( Roberts , Papadopoulos et al . 2009 ) . Salivary cortisol salivary amylase easy study saliva need . ( Clow , Hucklebridge et al . ; Kirschbaum Hellhammer 1989 ; O'Donnell , Kammerer et al . 2009 ) . The investigator test saliva amylase , find robust useful marker function SAM system ( O'Donnell , Kammerer et al . 2009 ) . However still insufficient research diurnal profile cortisol amylase child suffer ADHD . This cause serious lack information clinical child adolescent psychiatry paediatrics well research community . Atomoxetine originally develop use antidepressant show excellent therapeutic effect attention deficit hyperactivity child suffer ADHD . It selective re-uptake inhibitor noradrenaline synaptic cavity ( NARI ) . Research possible effect medication Atomoxetine child diurnal profile cortisol amylase - investigator ' best knowledge - carry . The possible effect diurnal profile cortisol amylase could link treatment success general improvement individual symptom ADHD . It may also contribute good understand possible side effect . The investigator propose study - within subject design - five time daily saliva collection two consecutive weekday medication commences . Measurements repeat week one , four twelve medication Atomoxetine . Additional questionnaire data collection ( Conners , CBCL ) , feasible , test ( KI TAP ) carry . The study provide insight possible effect compound ( Atomoxetine ) stress system . It may identify easily measurable biological marker treatment success , provide research possible marker respondent non respondent . The investigator control motor activity use actometers . Hypotheses test 1 . The cortisol awaken reaction ( CAR ) significantly different , immediately four twelve week begin mediation Atomoxetine boys age seven ten . 2 . The overall cortisol level different three measurement time point . 3 . The diurnal profile salivary amylase overall amylase level significantly different three measurement time point . 4 . There group effect regard diurnal profile distinguish responder Atomoxetine ( response=50 % reduction symptom ) non responder . Plan Research Ethical approval The protocol obtain approval relevant ethical committee prior begin study . Location A network paediatrician 's n Switzerland . Subjects test Eligibility criterion : Boys eligible , age seven ten , without comorbid psychiatric and/or somatic condition responsible paediatrician and/or child psychiatrist give indication treatment Atomoxetine parent follow advice . In order exclude effect prior psycho pharmacotherapy psychotropic drug naive boy choose . The diurnal variation seem change child grow old ( unpublished observation group ) . Therefore , want try get sample homogenous possible . Exclusion criterion : Suicidal risk , depression , history epileptic seizure , co morbid psychiatric somatic condition , history psychotropic medication . Power : With n=50 investigator expect power 80 % 5 % significance SD 0.6 . In study postpartum depression ( Taylor et al , 2009 ) reach significant difference group n= 30 n=21 . Sample : • 50 boy , seven ten age , clinical diagnosis ADHD ( ICD 10 DSMV ) Measurements Biological measure Method measurement saliva cortisol saliva amylase : The methodology apply ( O'Donnell , Kammerer et al . 2009 ; Taylor , Glover et al . 2009 ) Actometer measurement use actometers provide www.resmed.ch Psychological measure Assessment tool quantify ADHD symptom include German version CPRS-R : L ( Conners 1998 ; Conners , Sitarenios et al . 1998 ; Conners , Sitarenios et al . 1998 ) , CTRS-R : L ( Conners , Sitarenios et al . 1998 ) , SDQ , parent teacher version ( Goodman 1997 ) , Achenbach , T.M. , &amp; Rescorla , L. A . ( 2001 ) . Manual ASEBA School-Age Forms Profiles . Burlington , VT : University Vermont , Research Center Children , Youth , Families . ISBN 0-938565-73-7</detailed_description>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Boys eligible , age seven ten , without comorbid psychiatric and/or somatic condition responsible paediatrician and/or child psychiatrist give indication treatment atomoxetine . Suicidal risk , depression , history epileptic seizure , comorbid psychiatric somatic condition , history psychotropic medication .</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ADHD , cortisol , α-amylase , actometer</keyword>
</DOC>